A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients
| Autor: | Jane Yeo, Joseph J. Eron, Mary Beth Wire, Jean Michel Livrozet, Judith Millard, Eugenio Teofilo, Odin J. Naderer, Christian Trepo, Keikawus Arastéh, Robin Wood |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Adolescent Population HIV Infections Gastroenterology Amprenavir Abacavir Antiretroviral Therapy Highly Active Internal medicine medicine Humans Furans education Aged Sulfonamides education.field_of_study Ritonavir Reverse-transcriptase inhibitor business.industry Lamivudine Abacavir/Lamivudine Middle Aged Virology Regimen Infectious Diseases nervous system Female Carbamates business medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 39:591-594 |
| ISSN: | 1537-6591 1058-4838 |
| Popis: | The pharmacokinetics, antiviral activity, and safety of an amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d. regimen and an APV-RTV 1200/200 mg q.d. regimen were studied in a human immunodeficiency virus (HIV)-infected population. The geometric least-square mean ratio (90% confidence interval) of steady-state trough concentrations, compared with that of the amprenavir 1200 mg b.i.d. regimen, was 6.08 (4.94-7.49) for the twice-daily APV-RTV regimen, and it was 4.19 (2.90-6.08) for the daily APV-RTV regimen. The regimens were well tolerated, which supports APV-RTV as an option for twice-daily or daily therapy for HIV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|